Considering Headwinds In Asia, Harvard Bioscience Expects FY23 Revenue To Be Approximately Flat As Compared To 2022 Versus $116M-$120M Expected Earlier And Consensus Of $116.95M
Portfolio Pulse from Benzinga Newsdesk
Harvard Bioscience has revised its FY23 revenue forecast to be approximately flat compared to 2022, due to headwinds in Asia. This is a change from its earlier expectation of $116M-$120M, and is below the consensus estimate of $116.95M.
November 07, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Harvard Bioscience's revised FY23 revenue forecast is likely to negatively impact its stock price in the short term.
Harvard Bioscience's revised FY23 revenue forecast is lower than its previous forecast and the consensus estimate. This suggests that the company's financial performance may be weaker than expected, which could lead to a decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100